Page 118 - Case Lab Case Analysis

Between January 2016 and February 2017 alternative prescriptions to
EpiPens rise but do so most pointedly in the last two months of the
period.

Source: https://insight.athenahealth.com/prescriptions-jump-epipen-alternatives

Between January 1st 2017 and February 25th alternative EpiPen auto
injectors rise but Auvi-Q accounted for almost one third of that growth.

Conclusions

Mylan’s troubles were however not over as earlier in March 2017 the
FDA alerted consumers that Mylan were voluntarily recalling 13 lots of
Mylan’s EpiPen and EpiPen Junior as there is the potential that these
devices may contain a defective part that may result in the devices’

failure to activate. June 2017 also saw Senator Chuck Grassley (R-IA)
calculate that Mylan may have overcharged the government by about
$1.27 billion for EpiPens not the agreed $465 million settlement with the

DOJ in October 2016.